What is ABBV-CLS-628 used for?

ABBV-CLS-628 is indicated for Relapsing multiple sclerosis.

Who makes ABBV-CLS-628?

ABBV-CLS-628 is developed by AbbVie.

What are the side effects of ABBV-CLS-628?

Common side effects include Nausea, Headache, Diarrhea.

Last reviewed 2026-04-23 · How we verify

ABBV-CLS-628

AbbVie · Phase 2 active Small molecule

ABBV-CLS-628 is a small molecule targeting the S1P1 receptor.

ABBV-CLS-628 is a small molecule targeting the S1P1 receptor. Used for Relapsing multiple sclerosis.

At a glance

Generic name	ABBV-CLS-628
Sponsor	AbbVie
Drug class	S1P1 receptor antagonist
Target	S1P1
Modality	Small molecule
Therapeutic area	Autoimmune diseases
Phase	Phase 2

Mechanism of action

S1P1 receptor antagonists like ABBV-CLS-628 are being investigated for their potential to treat multiple sclerosis and other autoimmune diseases by inhibiting the S1P1 receptor, which plays a key role in the migration of immune cells.

Approved indications

Relapsing multiple sclerosis

Common side effects

Nausea
Headache
Diarrhea

Key clinical trials

A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results